结核病与肺部健康杂志 ›› 2015, Vol. 4 ›› Issue (4): 219-222.doi: 10.3969/j.issn.2095-3755.2015.04.003

• 论著 • 上一篇    下一篇

耐多药肺结核化学治疗不良反应及处理

邝浩斌,谭守勇,谢育红,汪敏,张宏,袁圆,李艳,覃红娟,冯治宇,叶锦泉   

  1. 510095 广州市胸科医院 呼吸疾病国家重点实验室
  • 收稿日期:2015-11-19 出版日期:2015-12-30 发布日期:2015-12-30
  • 通信作者: 谭守勇,Email:tanshouyong@163.com
  • 基金资助:
    广州市医药卫生科技重大项目(20151A031002)

Adverse drug reactions of chemotherapy and treatment in patients with multidrug resistant tuberculosis

KUANG Hao-bin, TAN Shou-yong, XIE Yu-hong, WANG Min, ZHANG Hong, YUAN Yuan, LI Yan, QIN Hong-juan, FENG Zhi-yu, YE Jin-quan   

  1. Department of Tuberculosis,Guangzhou Chest Hospital, State Key Laboratory of Respiratory Disease, Guangdong 510095,China
  • Received:2015-11-19 Online:2015-12-30 Published:2015-12-30

摘要: 目的了解耐多药肺结核(MDR-TB)化学治疗的不良反应情况。方法回顾性研究广州市胸科医院2008年11月至2013年7月纳入全球基金MDR-TB治疗项目并且完成疗程的96例患者。患者的治疗方案为6 Km(Am)-Z-Lfx(Ofx)-PAS(Cs)-Pto/18Z-Lfx(Ofx)-PAS(Cs)-Pto。根据病历资料,收集患者的一般情况、治疗方案、药物不良反应(ADR)、处理方法,并进行分析。结果 96例患者中出现ADR 83例(86.5%),无ADR 13例(13.5%);治愈者与治疗失败者ADR的发生率分别是87.1%(54/62)和85.3%(29/34),差异无统计学意义(χ2=0.06,P=0.806);在0~1个月、2~6个月的疗程治愈的患者ADR发生率分别是40.7%(22/54)和46.3%(25/54);治疗失败者分别是34.5%(10/29)和55.2%(16/29),两者比较差异无统计学意义(χ2=0.31,P=0.577和χ2=0.60,P=0.441)。常见的ADR是胃肠道反应、关节痛、头昏头痛、肝损伤,发生率分别是50.0%(48/96)、25.0% (23/96)、13.5% (13/96)、15.6%(15/96);以Cfz、Pto、PAS、Clr、Lfx、Km、Z的ADR发生率较高,分别是100%(7/7)、48.7%(39/80)、48.4%(31/64)、47.1%(8/17)、28.5%(20/70)、28.3%(17/60)、26.2%(22/84);107例次(69.5%)需停用相关的药物,替换其他药物。结论 MDR-TB治疗的ADR发生率较高、种类多,需采用正确的对策和进行规范处理。

Abstract: Objective To explore adverse drug reactions (ADR) of chemotherapy and treatment in patients with multidrug resistant tuberculosis (MDR-TB).Methods We analyzed retrospectively 96 patients enrolled MDR-TB project of Global fund and completed treatment in Guangzhou chest hospital from November 2008 to July 2013. The chemotherapy regimen was 6 Km(Am)-Z-Lfx(Ofx)-PAS(Cs)-Pto/18Z-Lfx(Ofx)-PAS(Cs)-Pto. The data including general condition, regimen, ADR and treatment were analyzed.Results There were 83 cases (86.5%,83/96) suffered from ADR in 96 patients who completed the course of treatment. The occurrence rate of ADR for the cases of cure and failure were 87.1% (54/62) and 85.3% (29/34) without statistical significance (χ2=0.06, P=0.806), respectively. In 0-1st month, 2nd-6th month of treatment, the incidences of ADR were 40.7% (22/54) and 46.3% (25/54) among patients who cured; 34.5% (10/29) and 55.2% (16/29) among patients who were failure, respectively. There was no statistical difference (χ2=0.31, P=0.577 and χ2=0.60,P=0.441).The common ADRs were nausea/vomiting (50.0%, 48/96), arthralgia (25.0%, 23/96), dizziness and headache (13.5%,13/96), and hepatitis (15.6%,15/96). The ADRs caused by Cfz,Pto,PAS,Clr,Lfx,Km,Z were common, and the incidence of these drugs were 100% (7/7), 48.7% (39/80),48.4% (31/64),47.1% (8/17), 28.5% (20/70), 28.3% (17/60), and 26.2% (22/84). 107 cases (69.5%) needed to stop relative drugs and then replaced with other drugs.Conclusion The occurrence rate of ADR of the chemotherapy for MDR-TB are relatively higher and vary. It needs to adopt correct strategy and standardized treatment.